Chronic Graft Versus Host Disease
49
15
22
15
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
13 trials with published results (27%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
12.2%
6 terminated out of 49 trials
71.4%
-15.1% vs benchmark
10%
5 trials in Phase 3/4
87%
13 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (49)
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Improving Outcomes Assessment in Chronic GVHD
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
Upfront Ruxolitinib for Chronic Graft-vs-host Disease
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)